{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:05:52Z","timestamp":1779296752536,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 187152"],"award-info":[{"award-number":["CA 187152"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 222467"],"award-info":[{"award-number":["CA 222467"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>PRKCI<\/jats:italic>, the gene for protein kinase C\u03b9 (PKC\u03b9), is frequently amplified in ovarian cancer and recent studies have shown that PKC\u03b9 participates in ovary tumorigenesis. However, it is unknown whether PKC\u03b9 is differentially involved in the growth\/survival between <jats:italic>PRKCI<\/jats:italic>-amplified and non-amplified ovarian cancer cells. In this study, we analyzed ovarian cancer patient dataset and revealed that <jats:italic>PRKCI<\/jats:italic> is the only PKC family member significantly amplified in ovarian cancer and <jats:italic>PRKCI<\/jats:italic> amplification is associated with higher PKC\u03b9 expression. Using a panel of ovarian cancer cell lines, we found that abundance of PKC\u03b9 is generally associated with <jats:italic>PRKCI<\/jats:italic> amplification. Interestingly, silencing PKC\u03b9 led to apoptosis in <jats:italic>PRKCI<\/jats:italic>-amplified ovarian cancer cells but not in those without <jats:italic>PRKCI<\/jats:italic> amplification, thus indicating an oncogenic addiction to PKC\u0269 in <jats:italic>PRKCI<\/jats:italic>-amplified cells. Since small-molecule inhibitors characterized to selectively block atypical PKCs did not offer selectivity nor sensitivity in <jats:italic>PRKCI<\/jats:italic>-amplified ovarian cancer cells and were even cytotoxic to non-cancerous ovary surface or fallopian tube epithelial cells, we designed an EpCAM aptamer-PKC\u03b9 siRNA chimera (EpCAM-siPKC\u03b9 aptamer). EpCAM-siPKC\u03b9 aptamer not only effectively induced apoptosis of <jats:italic>PRKCI<\/jats:italic>-amplified ovarian cancer cells but also greatly deterred intraperitoneal tumor development in xenograft mouse model. This study has demonstrated a precision medicine-based strategy to target a subset of ovarian cancer that contains <jats:italic>PRKCI<\/jats:italic> amplification and shown that the EpCAM aptamer-delivered PKC\u03b9 siRNA may be used to suppress such tumors.<\/jats:p>","DOI":"10.1038\/s41392-020-0197-8","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:05:31Z","timestamp":1597964731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Addiction to protein kinase C\u0269 due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer"],"prefix":"10.1038","volume":"5","author":[{"given":"Hina","family":"Rehmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Padia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Calbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingtao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"197_CR1","unstructured":"Society, A. C. Cancer facts & figures 2019. p. 20\u201322 (American Cancer Society, 2019)."},{"key":"197_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet384, 1376\u20131388 (2014).","journal-title":"Lancet"},{"key":"197_CR3","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/ijc.22609","volume":"120","author":"K Nakayama","year":"2007","unstructured":"Nakayama, K. et al. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer120, 2613\u20132617 (2007).","journal-title":"Int. J. Cancer"},{"key":"197_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/path.1681","volume":"205","author":"MB Lambros","year":"2005","unstructured":"Lambros, M. B. et al. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J. Pathol.205, 29\u201340 (2005).","journal-title":"J. Pathol."},{"key":"197_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network.","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"197_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc3721","volume":"14","author":"VN Kristensen","year":"2014","unstructured":"Kristensen, V. N. et al. Principles and methods of integrative genomic analyses in cancer. Nat. Rev. Cancer14, 299\u2013313 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"197_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jbior.2015.10.009","volume":"60","author":"AP Fields","year":"2016","unstructured":"Fields, A. P., Justilien, V. & Murray, N. R. The chromosome 3q26 OncCassette: a multigenic driver of human cancer. Adv. Biol. Regul.60, 47\u201363 (2016).","journal-title":"Adv. Biol. Regul."},{"key":"197_CR8","doi-asserted-by":"publisher","first-page":"12519","DOI":"10.1073\/pnas.0505641102","volume":"102","author":"AM Eder","year":"2005","unstructured":"Eder, A. M. et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl Acad. Sci. USA102, 12519\u201312524 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"197_CR9","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1158\/0008-5472.CAN-05-4527","volume":"66","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res.66, 4627\u20134635 (2006).","journal-title":"Cancer Res."},{"key":"197_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1541-7786.MCR-13-0371-T","volume":"11","author":"Y Wang","year":"2013","unstructured":"Wang, Y., Hill, K. S. & Fields, A. P. PKCiota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol. Cancer Res.11, 1624\u20131635 (2013).","journal-title":"Mol. Cancer Res."},{"key":"197_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/onc.2016.224","volume":"36","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene36, 534\u2013545 (2017).","journal-title":"Oncogene"},{"key":"197_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1101\/gad.296640.117","volume":"31","author":"S Sarkar","year":"2017","unstructured":"Sarkar, S. et al. PRKCI promotes immune suppression in ovarian cancer. Genes Dev.31, 1109\u20131121 (2017).","journal-title":"Genes Dev."},{"key":"197_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.32","volume":"3","author":"H Sun","year":"2014","unstructured":"Sun, H. et al. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol. Ther. Nucleic Acids3, e182 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"197_CR14","doi-asserted-by":"publisher","first-page":"8898","DOI":"10.1073\/pnas.132067399","volume":"99","author":"B Wlotzka","year":"2002","unstructured":"Wlotzka, B. et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl Acad. Sci. USA99, 8898\u20138902 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"197_CR15","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1023\/A:1007657109012","volume":"17","author":"DW Drolet","year":"2000","unstructured":"Drolet, D. W. et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res.17, 1503\u20131510 (2000).","journal-title":"Pharm. Res."},{"key":"197_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.4155\/tde.13.118","volume":"4","author":"JP Dassie","year":"2013","unstructured":"Dassie, J. P. & Giangrande, P. H. Current progress on aptamer-targeted oligonucleotide therapeutics. Ther. Deliv.4, 1527\u20131546 (2013).","journal-title":"Ther. Deliv."},{"key":"197_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.7150\/thno.11692","volume":"5","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model. Theranostics5, 1456\u20131472 (2015).","journal-title":"Theranostics"},{"key":"197_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou, J. & Rossi, J. Aptamers as targeted therapeutics: current potential and challenges. Nat. Rev. Drug Discov.16, 181\u2013202 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"197_CR19","doi-asserted-by":"publisher","first-page":"66ra66","DOI":"10.1126\/scitranslmed.3001581","volume":"3","author":"CP Neff","year":"2011","unstructured":"Neff, C. P. et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med.3, 66ra66 (2011).","journal-title":"Sci. Transl. Med."},{"key":"197_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrd2241","volume":"6","author":"JM Reichert","year":"2007","unstructured":"Reichert, J. M. & Valge-Archer, V. E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov.6, 349\u2013356 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"197_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00404-013-2868-y","volume":"288","author":"P Tsikouras","year":"2013","unstructured":"Tsikouras, P. et al. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch. Gynecol. Obstet.288, 581\u2013585 (2013).","journal-title":"Arch. Gynecol. Obstet."},{"key":"197_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1158\/0008-5472.CAN-05-3405","volume":"66","author":"M Stallings-Mann","year":"2006","unstructured":"Stallings-Mann, M. et al. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res.66, 1767\u20131774 (2006).","journal-title":"Cancer Res."},{"key":"197_CR23","doi-asserted-by":"publisher","first-page":"7403","DOI":"10.1158\/0008-5472.CAN-08-1449","volume":"68","author":"W Guo","year":"2008","unstructured":"Guo, W., Wu, S., Liu, J. & Fang, B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res.68, 7403\u20137408 (2008).","journal-title":"Cancer Res."},{"key":"197_CR24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1349-7006.2011.01897.x","volume":"102","author":"S Shigdar","year":"2011","unstructured":"Shigdar, S. et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci.102, 991\u2013998 (2011).","journal-title":"Cancer Sci."},{"key":"197_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/cdd.2009.119","volume":"16","author":"J Moscat","year":"2009","unstructured":"Moscat, J., Diaz-Meco, M. T. & Wooten, M. W. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ.16, 1426\u20131437 (2009).","journal-title":"Cell Death Differ."},{"key":"197_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ijc.2910430218","volume":"43","author":"R Seshadri","year":"1989","unstructured":"Seshadri, R., Matthews, C., Dobrovic, A. & Horsfall, D. J. The significance of oncogene amplification in primary breast cancer. Int. J. Cancer43, 270\u2013272 (1989).","journal-title":"Int. J. Cancer"},{"key":"197_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res.74, 1141\u20131152 (2014).","journal-title":"Cancer Res."},{"key":"197_CR28","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","volume":"68","author":"IB Weinstein","year":"2008","unstructured":"Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res.68, 3077\u20133080 (2008).","journal-title":"Cancer Res."},{"key":"197_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39\u201351 (2007).","journal-title":"N. Engl. J. Med."},{"key":"197_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer7, 169\u2013181 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"197_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrc2820","volume":"10","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V., Haber, D. A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer10, 241\u2013253 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"197_CR32","doi-asserted-by":"publisher","first-page":"ra16","DOI":"10.1126\/scisignal.2004520","volume":"6","author":"S Hong","year":"2013","unstructured":"Hong, S. et al. Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. Sci. Signal.6, ra16 (2013).","journal-title":"Sci. Signal."},{"key":"197_CR33","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/onc.2016.323","volume":"36","author":"D Fang","year":"2017","unstructured":"Fang, D. et al. Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1\/2 and Src signaling pathways. Oncogene36, 1546\u20131558 (2017).","journal-title":"Oncogene"},{"key":"197_CR34","doi-asserted-by":"publisher","first-page":"87232","DOI":"10.18632\/oncotarget.13601","volume":"7","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition. Oncotarget7, 87232\u201387245 (2016).","journal-title":"Oncotarget"},{"key":"197_CR35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41388-018-0499-2","volume":"38","author":"DD Zhang","year":"2019","unstructured":"Zhang, D. D., Li, Y., Xu, Y., Kim, J. & Huang, S. Phosphodiesterase 7B\/microRNA-200c relationship regulates triple-negative breast cancer cell growth. Oncogene38, 1106\u20131120 (2019).","journal-title":"Oncogene"},{"key":"197_CR36","doi-asserted-by":"publisher","first-page":"20801","DOI":"10.18632\/oncotarget.4600","volume":"6","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget6, 20801\u201320812 (2015).","journal-title":"Oncotarget"},{"key":"197_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.7150\/thno.17826","volume":"7","author":"J Zheng","year":"2017","unstructured":"Zheng, J., Zhao, S., Yu, X., Huang, S. & Liu, H. Y. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics7, 1373\u20131388 (2017).","journal-title":"Theranostics"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0197-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:19:09Z","timestamp":1670249949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0197-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-0197-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}